Transgender youth on gender-affirming hormone therapy have differences in their percent fat and lean mass compared with cisgender youth.
Receiving 12 weeks of probiotic supplement can improve body mass index as well as components of the inflammatory and glycolipid metabolism in obese children.
The FDA has expanded the approval of Crysvita (burosumab; Ultragenyx and Kyowa Kirin) to include treatment in pediatric patients as young as 6 months with X-linked hypophosphatemia.
Increasing evening chronotypes and social jet lag are associated with increased adiposity in adolescent girls.
Colophonium, a fast-acting adhesive and known sensitizing allergen, may cause dermatologic reactions in children using devices to manage diabetes.
Maternal cholecalciferol supplementation may have lasting benefits for offspring musculoskeletal health.
There are significant relationships between bone marrow density, visceral adipose tissue, and bone indices in children.
Daily liraglutide, in addition to metformin and insulin, reduces HbA1c and improves glycemic control in young patients with type 2 diabetes.
Researchers explored the association between food insecurity and the risk for obesity and prediabetes in adolescents and young adults.
The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years